title: Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer.
authors.forename: Kosei
authors.initials: K
authors.lastname: Matsue
authors.forename: Keitaro
authors.initials: K
authors.lastname: Matsuo
authors.forename: Hideaki
authors.initials: H
authors.lastname: Fujiwara
authors.forename: Kan-Ichi
authors.initials: K
authors.lastname: Iwama
authors.forename: Brian Y
authors.initials: BY
authors.lastname: Hayama
authors.forename: Shun-Ichi
authors.initials: S
authors.lastname: Kimura
authors.forename: Masayuki
authors.initials: M
authors.lastname: Yamakura
authors.forename: Masami
authors.initials: M
authors.lastname: Takeuch
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001549:Benzamides; D001780:Blood Coagulation Tests; D003430:Cross-Sectional Studies; D005260:Female; D005500:Follow-Up Studies; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D013921:Thrombocytopenia / Q000139:chemically induced / Q000517:prevention & control; D016896:Treatment Outcome; D028761:Withholding Treatment; D000979:alpha-2-Antiplasmin / Q000235:genetics / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000979:alpha-2-Antiplasmin; D000068877:Imatinib Mesylate